Profusa, Inc. Common Stock (PFSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has a cash flow conversion efficiency ratio of 0.313x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.62 Million) by net assets ($-33.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Profusa, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Profusa, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Profusa, Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Profusa, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profusa, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LCK Global Kedaton
JK:LCKM
|
0.002x |
|
Moonpig Group PLC
LSE:MOON
|
-0.276x |
|
ClearOne Inc
NASDAQ:CLRO
|
-0.218x |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
|
SunLink Health Systems Inc
NYSE MKT:SSY
|
-0.190x |
|
Norfolk Metals Ltd
AU:NFL
|
0.023x |
|
Arb Bhd
KLSE:7181
|
-0.071x |
|
Lifecare AS
OL:LIFE
|
3.325x |
Annual Cash Flow Conversion Efficiency for Profusa, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see PFSA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-119.20 Million | $-2.07 Million | 0.017x | -56.69% |
| 2023-12-31 | $-110.00 Million | $-4.40 Million | 0.040x | -48.16% |
| 2022-12-31 | $-99.77 Million | $-7.70 Million | 0.077x | -39.59% |
| 2021-12-31 | $-83.66 Million | $-10.69 Million | 0.128x | -- |
About Profusa, Inc. Common Stock
Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor gluco… Read more